期刊文献+

罗格列酮治疗后2型糖尿病高血压患者血清基质金属蛋白酶-2及其相关指标的变化 被引量:1

下载PDF
导出
摘要 目的观察2型糖尿病高血压患者血清基质金属蛋白酶-2及其组织抑制因子-1的水平及罗格列酮治疗后的变化。方法64例2型糖尿病(T2DM)患者分成3组:①T2DM无合并症组(即单纯T2DM)24例;②T2DM合并高血压非罗格列酮治疗组20例;③T2DM合并高血压罗格列酮治疗组20例。采用酶联免疫吸附(ELISA)法测定基质金属蛋白酶-2(MMP-2)及其组织抑制因子-1(TIMP-1)和实验室相关指标,观察罗格列酮治疗前后MMP-2,TIMP-1水平变化及与非罗格列酮治疗组之间变化的差别。结果应用罗格列酮治疗组治疗16周后的血清MMP-2,TIMP-1水平分别为(37.9±3.9)ng/ml和(410.0±80.9)ng/ml较治疗前水平MMP-2(27.5±4.3)ng/ml明显升高(P<0.05);而TIMP-1水平较治疗前(468.1±100.6)ng/ml则明显降低(P<0.05)。结论罗格列酮治疗除能改善血糖及血压外,可升高MMP-2和降低TIMP-1水平。
出处 《广东医学》 CAS CSCD 北大核心 2007年第5期815-817,共3页 Guangdong Medical Journal
基金 河北省唐山市科学技术研究与发展计划项目(编号:04134623C)
  • 相关文献

参考文献11

  • 1RASKIN P,RENDELL M,RIDDLE M C,et al.A randomized trial of rodiglitazone therapy in patients with inadequately insulintreated type 2 diabetes[J].Diabetes Care,2001,24 (7):1 226-1 232.
  • 2朱耀国,任叶慧,姜军权.罗格列酮治疗2型糖尿病的机制及临床疗效[J].中国新药与临床杂志,2003,22(12):751-753. 被引量:31
  • 3HALLSTEN K,VIRTANEN K A,LONNQVIST F,et al.Rosiglitazone but not mefformin enhances insulin and exercise stimulated skeletal muscle glucose uptake in patients with newly diagnosed type2 diabetes[J].Diabetes,2002,51(12):3 479 -3 485.
  • 4HAFFNER S M,GREENBERG AS,WESTON W M,et al.Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type2 diabetes mellitus[J].Circulation,2002,106(6):679 -684.
  • 5UZUKI D,MIYAZAKI M,JINDE K,et al.In site hybridization studies of matrix metalloproteinase-3,tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen in diabetic nephropathy.Kidney Int,1997,52:111-119.
  • 6MCLENNAN S,YUE D K,TURTLE J R,et al.Effect of glucose on matrix metalloproteinase activity in mesangial cell[J].Nephron,1997,79(2):293 -298.
  • 7沈庆乐,张存琪.血清基质金属蛋白酶与糖尿病血管病变的关系[J].微循环技术杂志(临床与实验),2004,8(5):349-349. 被引量:19
  • 8陈雅静,刘宽芝,张新莉,郝伟.血清基质金属蛋白酶-9与2型糖尿病大血管病变的相关性研究[J].临床内科杂志,2003,20(8):437-438. 被引量:32
  • 9周秀艳,侯振江,李艳华,邢桂芝,张庆峰,韩素桂,于文霞,楮金龙.血清基质金属蛋白酶-2及其组织抑制因子-1与糖尿病高血压和肾病的相关性研究[J].中国老年学杂志,2006,26(4):458-460. 被引量:7
  • 10DAVIES M.New diagnostic oriteria for diabetes are tley doing what they should[J].Lancet,1999,354(6):610 -616.

二级参考文献35

  • 1沈庆乐,张存琪.血清基质金属蛋白酶与糖尿病血管病变的关系[J].微循环技术杂志(临床与实验),2004,8(5):349-349. 被引量:19
  • 2[1]World Health Organization. The World Health Report: Conquering suffering, enriching humanity[M]. Geneva: WHO,1997.6.
  • 3[2]World Health Organization. The World Health Report: Life in the 21st century, a vision for all[M]. Geneva:WHO, 1998.5.
  • 4[3]SALTIEL AR, OLEFSKY JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes[J]. Diabetes,1996,45(12):1661-1669.
  • 5[4]HARING HU, MEHNERT H. Pathogenesis of type 2(non-insulin-dependent) diabetes mellitus:candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle[J]. Diabetologia,1993,36(3):176-182.
  • 6[5]UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. Lancet,1998,352(9131):837-853.
  • 7[6]SPIEGELMAN BM. PPAR-gamma:adipogenic regulator and thiazolidinedione receptor[J]. Diabetes,1998,47(4):507-514.
  • 8[7]YOUNG PW, CAWTHORNE MA, COYLE PJ, et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling[J]. Diabetes,1995,44(9):1087-1092.
  • 9[8]LISTER CA. Rosiglitazone increases pancreatic islet area, number and insulin content, but not insulin gene expression[J]. Diabetologia,1998,41 Suppl 1: A660.
  • 10[9]SMITH S, BOAM D, BRETHERTON-WATT D, et al. Rosiglitazone increases pancreatic islet area, density and insulin content, but not insulin gene expression[J]. Diabetes,1998, 47 Suppl 1:A18.

共引文献79

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部